Prestige Consumer Healthcare Inc. (NYSE:PBH) Short Interest Up 18.0% in February

Prestige Consumer Healthcare Inc. (NYSE:PBH) was the target of a significant growth in short interest in the month of February. As of February 27th, there was short interest totaling 2,374,940 shares, a growth of 18.0% from the February 12th total of 2,011,903 shares. Currently, 5.1% of the shares of the stock are short sold. Based on an average daily volume of 464,756 shares, the days-to-cover ratio is presently 5.1 days. Based on an average daily volume of 464,756 shares, the days-to-cover ratio is presently 5.1 days. Currently, 5.1% of the shares of the stock are short sold.

Prestige Consumer Healthcare Stock Up 2.1%

NYSE PBH traded up $1.31 during trading on Tuesday, hitting $62.22. The stock had a trading volume of 498,325 shares, compared to its average volume of 420,290. The company has a market capitalization of $2.94 billion, a PE ratio of 16.46, a P/E/G ratio of 1.92 and a beta of 0.41. Prestige Consumer Healthcare has a 12 month low of $57.25 and a 12 month high of $89.37. The company’s 50-day moving average price is $66.00 and its two-hundred day moving average price is $63.40. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The business had revenue of $283.44 million during the quarter, compared to the consensus estimate of $286.93 million. During the same period in the prior year, the firm earned $1.22 EPS. The business’s revenue for the quarter was down 2.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. As a group, sell-side analysts forecast that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Insider Transactions at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,000 shares of the stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total value of $65,930.00. Following the completion of the transaction, the vice president owned 41,048 shares in the company, valued at $2,706,294.64. This represents a 2.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 1.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of large investors have recently modified their holdings of the business. UMB Bank n.a. grew its holdings in shares of Prestige Consumer Healthcare by 110.1% in the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after acquiring an additional 219 shares in the last quarter. Bayforest Capital Ltd acquired a new position in Prestige Consumer Healthcare during the fourth quarter valued at approximately $29,000. First Horizon Corp bought a new position in Prestige Consumer Healthcare in the third quarter valued at approximately $32,000. Barrow Hanley Mewhinney & Strauss LLC grew its stake in Prestige Consumer Healthcare by 106.8% in the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after purchasing an additional 283 shares in the last quarter. Finally, Geneos Wealth Management Inc. increased its position in shares of Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently weighed in on PBH. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Jefferies Financial Group lowered their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Friday, January 30th. Three research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $80.60.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).